The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
|Videos|February 11, 2016
- Gastrointestinal Cancers: mCRC (Issue 6)
- Volume 1
- Issue 6
Dr. John Marshall on Individualizing Treatment for Patients With Colorectal Cancer
Author(s)John Marshall, MD
John Marshall, MD, discusses the individualization of treatment of patients with colorectal cancer (CRC).
Advertisement
John Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, discusses the individualization of treatment of patients with colorectal cancer (CRC). Marshall says while maintaining VEGF-inhibition does promote a better overall survival advantage, there is not a major difference between many of the frontline therapies. He adds that the order in which medical professionals decide to use these treatments is entirely up to the individual and based on what the patient responds to.
Articles in this issue
over 10 years ago
Dr. Jennifer Wu on Proliferations and Mutations in Colorectal Cancerover 10 years ago
Early Development of Regorafenib: Was the Correct Dose Selected?over 10 years ago
Clinical Review: Regorafenib in Refractory mCRCover 10 years ago
Optimizing Outcomes With Regorafenib in Metastatic CRCover 10 years ago
Patient Populations Provide Sequencing Clues in Chemorefractory CRCover 10 years ago
Dr. Cathy Eng on Bevacizumab Plus FOLFOXIRI for Patients With mCRCAdvertisement
Related to this article
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end point but reduced neurotoxicity.
The investigational chemoimmunotherapy antibody-drug conjugate demonstrated enhanced tumor inhibition in preclinical models.
The RELIGHT study found that adding retlirafusp alfa to chemotherapy extended overall and progression-free survival in previously untreated gastric and GEJ cancers.
This marks the fourth submission to the FDA for approval of rivoceranib plus camrelizumab for this first-line indication in hepatocellular carcinoma.
The FDA granted FTD to opantistomig, a PD-L1/4-1BB bispecific antibody, for first-line treatment of biliary tract cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5